Human herpesviruses CD3+; CD4+ and CD8+ cell count) were considerably lower in RTR before RT. At 3 months after RT CD19+ and CD25+ cell counts were significantly increased in the HHV-7 group compared with the control group (P < 0.05). Significant differences were not found in clinical and immunological outcomes between patients with active ß-herpesviruses infection and those without active ß-herpesviruses infection.
INTRODUCTION
Human herpesviruses (HHV)-6 and -7 belong to the Betaherpesvirinae subfamily and are closely related to another member of the subfamily, cytomegalovirus (CMV). Infection with HHV-6 and HHV-7 commonly occurs in childhood and then subsequently results in life-long latency such that the seroprevalence rate in adults is over 90% (Yamanishi, 2001 ).
Primary HHV-6 infection has been associated with febrile illness, including exanthem subitum and infection, which are most likely transmitted by means of saliva. The infection usually occurs during the first two years of life. The virus uses CD46 as a cellular receptor and therefore HHV-6 may also infect other cell types, such as monocytes, epithelial and endothelial cells (Santoro et al., 1999) . The clinical course of primary HHV-6 infection is generally benign and self-limited. However, several severe complications have been reported, including encephalitis/encephalopathy, hepatitis and thrombocytopenia (Yoshikawa, 2003) . Infection with HHV-7 is also widespread in the population, with primary infection occurring early in life, probably through salivary transmission. HHV-7 has also been associated with febrile illness in children and is another etiologic agent of exanthem subitum (Tanaka et al., 1994) . The virus uses CD4 as a cellular receptor to infect T cells (Lusso et al., 1994) .
In adult solid organ transplant recipients, while primary infection is uncommon, reactivation of endogenous latent viruses seems to occur very frequently with infection rates of 30-50% reported in studies (Mendez et al., 2001; Razonable et al., 2005) . The stimulus for reactivation of betaherpesviruses is an immunosuppressive (IS) regimen in renal transplant (RT) recipients. However, these viruses possess immunomodulating properties, including the ability to alter the expression of immune activation molecules, modulate expression of several cytokines and chemokines and induce apoptosis in lymphocytes, which may contribute to immunosuppression. Productive infection of CD4 T-cells results in cytopathic effects and cell destruction (Lusso, 2006) . It has been suggested that the HHV-6 infection and activation result in clinical symptoms, including fever, skin rash, interstitial pneumonitis, bone marrow suppression, encephalitis, and rejection (Snydman et al., 2001) . In contrast to studies of HHV-6 infection in organ-transplant recipients, the number of studies examining HHV-7 infection in RT patients is limited. According to several recent studies, HHV-7 may act as a co-factor for CMV activation and CMV disease development in organ-transplant recipients (Osman et al., 1996) .
A growing body of evidence suggests that the major impact of HHV-6 and HHV-7 reactivation in transplantation is related to indirect immunomodulatory effects, such as their association with CMV disease, increased opportunistic infections, graft dysfunction and rejection (Mendez et al., 2001; Chapenko et al., 2009) .
In the present study we estimated the prevalence of latent and active HHV-6 and HHV-7 infection and the association of this infection with clinical and immunological parameters of graft outcome in renal transplant recipients.
MATERIALS AND METHODS
Fifty recipients receiving transplants at the Latvian Transplant Centre between January 2007 and December 2007 and 27 deceased renal allograft donors were included in this prospective study. The mean follow-up was 14 ± 2.5 months. Four early graft losses (until three months) occurred due to arterial graft thrombosis (n = 1) and death (n = 3). The causes of death were surgical peritonitis, pulmonary embolism, and one unknown cause as the patient was lost during follow up. Thus, further clinical, virological data and immunological tests were carried out in 46 of the 50 patients at 12 months. EDTA blood samples were collected from the patients before transplantation, at two weeks, and 3, 6 and 12 months after transplantation.
Nested polymerase chain reaction (nPCR) was used for the detection of viral genomic sequences in DNA isolated from peripheral blood leukocytes (PBL) and plasma (markers of latent/persistent and active infection, respectively). DNA was isolated from whole blood using the phenol-chloroform method. The QIAamp DNA Blood Mini Kit was used to extract DNA from plasma. b-globin PCR was applied to check DNA quality. The corresponding primer pairs were used for the detection of CMV, HHV-6 and HHV-7 genomic sequences (Secchiero et al., 1995 , Berneman et al., 1992 Studahl et al., 1995) in DNA isolated from whole blood and plasma. To exclude the possibility of contamination during the PCR, HHV-6 and HHV-7 negative DNA, as well as water controls, were included in each experiment. The amplification products were visualised in 1.7% agarose gel with ethidium bromide staining and analysed using the Kodak Electrophoresis Documentation and Analysis System (EDAS) 290 ASV.
Restriction endonuclease analysis was carried out using enzyme HindIII for the detection of HHV-6 virus variants.
This enzyme cuts HHV-6B 163 kbp amplimer into two fragments: 66 and 97 kbp and does not cut HHV-6A amplimer. In this way, HHV-6A and HHV-6B virus variants were distinguished.
The concentrations of lymphocyte subsets (CD3+, CD4+, CD8+, CD4+/CD8+, CD19+ and CD25+ in 1 mm 3 of blood) were measured using a flow cytometer (Becton& Dickinson). The numbers of total lymphocytes in each cell subset were expressed as absolute counts.
Clinical parameters (immunosuppressive regimens, acute rejection episodes, transplant function and late complications) were obtained through medical records.
Initial immunosuppression in all patients consisted of cyclosporine (CsA), mycophenolate mofetil (MMF) and prednisolone ( Statistical analysis. Data were expressed as means and standard deviations. Statistical differences between groups were assessed by analysis of variance (ANOVA) or Chisquare and t-test. A P-value < 0.05 was considered statistically significant.
The study was performed in accordance with the permission of the Local Ethics Committee and all the participants gave informed consent before the examination.
RESULTS
Latent/persistent ß-herpesviruses infection was detected in 23 of 27 (85%) transplant donors. CMV infection was found in seven (26%), HHV-6 in five (18.5%) and HHV-7 infection in 19 (70%) of donors. Active ß-herpesviruses infection occurred in four (15%) donors and of them two (7.5%) had active CMV and 2 had active HHV-7 infection.
ß-herpesviruses genomic sequence detection in PBL DNA samples of the 50 recipients before RT identified latent/persistent CMV infection in five (10%), HHV-6 in ten (20%) and HHV-7 infection in 39 (78%). At three months after RT active ß-herpesviruses infection (plasma viremia) was detected in 27 of 46 (58.7%) recipients, including twelve (26%) CMV, four (8.6%) HHV-6, nine (19.5%) HHV-7 and two (4.3%) dual HHV-6 and HHV-7 infection cases. To analyze the different clinical and immunological outcomes in patients with active HHV-6 and HHV-7 infection, the recipients were divided into three groups: Group I, with active HHV-6 infection (n = 4); Group II, with active HHV-7 infection (n = 9) and Group III (control) without active infection (n = 31). Two patients with dual active ß-herpesviruses infection were excluded due to small sample size.
Demografic and clinical data on recipients with and without active ß-herpesviruses infection are given in Table 1 . The three patient groups showed no significant differences in demographic parameters. The incidence of acute CMV infection and AR did not significantly differ between the patients who developed active ß-herpesviruses infection and those who did not. Interestingly, patients without active ß-herpesviruses infection showed a higher rate of acute CMV infection (29%) compared to patients in the group with active HHV-6 (0%) and HHV-7 (11.1%), respectively. Compared with the control group (32%), AR rate was slightly higher in patients with active HHV-6 infection (50%), but again, without statistical significance. There was also no significant difference in graft function at 3 and 12 months among the groups. The mean serum creatinine at 12 months was even lower in patients with active HHV-7 than in the control group (0.11 vs 0.13, P > 0.05). Table 2 gives the numbers of lymphocytes in subsets in the peripheral blood of control group patients with latent/persistent infection compared with the numbers of cells detected in the patients with active HHV-6 and HHV-7 infection at different times after RT.
Counts of CD3+, CD4+ and CD8+ cells were considerably lower before RT, but no significant changes between the three groups were found. Also, there were no significant changes in CD4+/CD8+; CD19+ and CD25+ counts in the study groups. At three months after RT, higher CD3+ and CD4+ cell counts were observed only in the HHV-7 group compared to control group (1.14 vs 0.73, P > 0.05 and 0.59 RT, renal transplant; HHV-6 and HHV-7, human herpesviruses vs 0.37, P > 0.05, respectively). Compared with the control group, the HHV-7 group had significantly increased CD19+ and CD25+ cell counts (P < 0.05 and P < 0.05, respectively).
DISCUSSION
Our study was hindered by the small study groups, which resulted in lack of statistical significance for many parameters. Consistent with our previous studies, we found high incidence of latent/persistent CMV, HHV-6 and HHV-7 infection in renal donors and recipients (26%; 18.5%; 70% and 10%; 20% and 78%, respectively). In contrast to our previous studies, a lower overall rate of active CMV, HHV-6 and HHV-7 infection was found in this study (26%; 19.5% and 4.3%, respectively). This may be due to the more intensive prophylaxis with valganciclovir used in recent years. We did not find significant association between active ß-herpesviruses infection and AR and graft function in recipients at different times after RT. The CD3+; CD4+ and CD8+ cell counts were considerably lower before RT, indicating impaired cellular immune function in patients with end-stage renal failure. Secondary immune failure in uremia is multi-faceted and is influenced by uremic intoxication per se, by altered renal metabolism of immunologically active proteins and by specific effects of renal replacement therapy (Girndt et al., 1999) . Interestingly, CD19+ and CD25+ cell counts were significantly higher in the HHV-7 group compared with the control group three months after RT (P < 0.05 and P > 0.05, respectively). It is possible that increase in expression of CD19+ and CD25+ cells in the HHV-7 group may be caused by down-regulation of cellular and humoral immune response due to viral indirect immunomodulatory effects (Lusso et al., 1994; Lusso, 2006; Mendez et al., 2001) . On the other hand, a normal or slightly lower overall lymphocyte subset count and relatively low rate of complications after RT suggests that the maintenance IS regimen with CsA, MMF and P does not induce over-immunosuppression in patients after RT.
